KM20 Xenograft Model Service for Colon Cancer

The KM20 Xenograft Model Service for Colon Cancer provides a robust preclinical platform for evaluating therapeutic efficacy against metastatic colorectal carcinoma, leveraging an aggressive cell line derived from a Dukes D stage primary tumor. Alfa Cytology specializes in constructing and validating KM20 xenograft models with rigorous quality control, enabling researchers to advance colon cancer drug development through reliable, reproducible preclinical data.

Overview of KM20 Xenograft Model for Colon Cancer

The KM20 cell line was established from a primary colon adenocarcinoma classified as Dukes D stage, indicating metastatic disease with spread to distant organs such as the liver. This cell line exhibits poorly differentiated morphology and aggressive growth characteristics, making it a valuable model for studying advanced-stage colorectal cancer. In xenograft settings, KM20 tumors demonstrate robust subcutaneous growth in immunodeficient mice and have been extensively utilized in preclinical studies evaluating targeted therapies, including PI3K inhibitors and tubulin-binding agents. The model is particularly notable for its utility in assessing drug responses in BRAFV600E-mutant colorectal cancer contexts, where KM20 has served as a representative cell line for combination therapy screening.

KM20 xenografts maintain key molecular features of metastatic colon cancer, including altered expression of apoptotic regulators and signaling pathway components. The model has contributed to understanding resistance mechanisms in colorectal carcinoma, particularly regarding PI3K/Akt-mediated survival pathways and NF-kappaB signaling. When propagated in vivo, KM20 tumors show consistent growth kinetics and are amenable to both subcutaneous and orthotopic implantation strategies, providing flexibility for studying primary tumor growth and metastatic dissemination patterns relevant to clinical colorectal cancer progression.

Figure 1. mRNA expression levels of 4 cell markers in 11 colorectal cancer cell lines. (Kim, Min Jung, et al., 2013)

Cell Line Information: KM20

The KM20 cell line represents a well-characterized human colon adenocarcinoma model with established preclinical utility. The following table summarizes key characteristics and specifications of this cell line:

Our Services

Alfa Cytology offers comprehensive KM20 xenograft model services tailored to your preclinical research objectives, from initial model construction and quality validation to endpoint analysis and data reporting. Our experienced team ensures consistent tumor growth, standardized protocols, and customizable study designs to support your colon cancer therapeutic development pipeline with reliable and actionable results.

Workflow of KM20 Xenograft Model Construction

The construction of KM20 xenograft models follows a standardized, multi-step workflow designed to ensure reproducible tumor growth and reliable preclinical data generation. Each phase is executed under strict quality control measures with documented traceability.

1. Cell Culture and Expansion: KM20 cells are expanded in vitro under standardized culture conditions using MEM medium with appropriate supplements. Cells are maintained at 37 degrees C in a humidified 5% CO2 incubator and passaged to achieve sufficient cell numbers for implantation while maintaining logarithmic growth phase.
2. Cell Harvest and Viability Assessment: Cultures are harvested using enzymatic dissociation, followed by centrifugation and resuspension in sterile PBS or serum-free medium. Cell viability is determined by trypan blue exclusion, with only preparations exceeding 95% viability accepted for xenograft construction.
3. Cell Preparation and Matrix Addition: Harvested KM20 cells are counted and resuspended at the optimal concentration for implantation. For subcutaneous models, cells are typically mixed with Matrigel or an equivalent extracellular matrix support at a 1:1 ratio to enhance initial engraftment and tumor take rates.
4. Animal Preparation and Implantation: Immunodeficient mice (commonly athymic nude or NOD-SCID strains) are acclimatized under pathogen-free conditions. KM20 cell suspensions are implanted subcutaneously into the flank region or orthotopically into the cecal wall, depending on the study design and research objectives.
5. Post-Implantation Monitoring: Mice are monitored daily for the first week following implantation, then twice weekly for general health status, body weight, and behavioral changes. Tumor growth is assessed by palpation and digital caliper measurements beginning when tumors become palpable.
6. Tumor Measurement and Growth Tracking: Tumor dimensions are recorded twice weekly using digital calipers, and tumor volume is calculated using the modified ellipsoid formula (length x width^2 x 0.5). Growth curves are generated to monitor tumor kinetics and identify the appropriate intervention window.
7. Treatment Administration and Endpoint Collection: When tumors reach the predetermined volume (typically 100-150 mm^3), mice are randomized into treatment and control groups. Test compounds are administered according to protocol, and tumors are harvested at study endpoints for downstream analysis including histopathology, biomarker assessment, and molecular profiling.

Figure 2: Schematic workflow illustrating the derivation and construction of the KM20 Xenograft Model at Alfa Cytology.

Case Study-KM20 Xenograft Model Development

Alfa Cytology has successfully established and validated KM20 xenograft models for multiple preclinical drug development programs targeting metastatic colorectal cancer. In a representative study, KM20 tumors were implanted subcutaneously in immunodeficient mice and allowed to establish before therapeutic intervention. Treatment arms received candidate compounds at various dose levels, while control groups received vehicle only. Tumor growth inhibition, body weight changes, and survival parameters were monitored throughout the study duration. Histological examination of harvested tumors confirmed maintenance of poorly differentiated adenocarcinoma morphology consistent with the parental cell line. Detailed efficacy data, pharmacokinetic correlations, and biomarker analysis results are available upon request for qualified research partners.

Why Choose Alfa Cytology?

Alfa Cytology delivers scientifically rigorous KM20 xenograft model services with a commitment to data integrity, protocol customization, and client collaboration throughout the preclinical research process.

• Validated KM20 xenograft models with documented tumor take rates and consistent growth kinetics across multiple study cohorts.
• Customizable study designs including subcutaneous, orthotopic, and metastatic model configurations to match specific research objectives.
• Standardized protocols aligned with preclinical best practices, ensuring reproducible results and regulatory-compliant data packages.
• Comprehensive endpoint analysis capabilities encompassing tumor growth inhibition, survival analysis, histopathology, and molecular biomarker profiling.
• Dedicated project management with transparent communication, detailed reporting, and flexible scheduling to accelerate your drug development timeline.

Contact Us

Ready to advance your colon cancer therapeutic program with a validated KM20 xenograft model? Contact us today to discuss your study requirements, receive a customized proposal, and learn how Alfa Cytology can support your preclinical research objectives. Reach out to our team to explore available study slots and data packages tailored to your specific needs.

For research use only. Not intended for any clinical use.